One of the most challenging issues in the modern world is the emergence and persistence of new diseases that affect us directly or impact those close to us. Among these, cancer stands out as one of the most prevalent, affecting a third of the entire population. It comes in many shapes and forms and often causes irreversible symptoms anywhere in the body. More specifically, a significant portion of these cancers is influenced by RAS mutations, which are present in nearly all pancreatic cancers, half of all colorectal cancers, and roughly thirty percent of all lung cancers. This race for a cure has pushed many biopharmaceutical companies to focus entirely on creating a cure for cancer.

Amongst the sectors in the global therapeutic market, oncology dominates as the highest